Methyltestosterone
| Methyltestosterone | |
|---|---|
| Molecular structure drawn from PubChem coordinates |
| Rotamer [] | |
|---|---|
| Conformer structure via 3Dmol.js |
| Physical properties [] | |
|---|---|
| Molecular mass | 302.50 g/mol [1] |
| Appearance | Crystals from hexane [1] |
| Odor | Odorless [1] |
| Melting point | 163 °C [1] |
| Solubility | 33.9 mg/L (at 25 °C) [1] |
| Predicted LogP | 3.4 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C20H30O2 |
| IUPAC name | (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one |
| SMILES | C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C)O)C |
| InChI | InChI=1S/C20H30O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h12,15-17,22H,4-11H2,1-3H3/t15-,16+,17+,18+,19+,20+/m1/s1 |
| InChIKey | GCKMFJBGXUYNAG-HLXURNFRSA-N |
| CAS number | 58-18-4 |
| UNII | V9EFU16ZIF |
| PubChem CID | 6010 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 150 minutes (~2.5–3 hours)[3] |
| Duration of action | 1–3 days |
| Metabolism | Liver |
| Excretion | Urine: 90%, Feces: 6% |
| Routes of administration | By mouth, buccal, sublingual |
| Toxicity [] | |
|---|---|
| LD50 | Mouse: - ip: 430 mg/kg [1] |
Methyltestosterone (also known as 17-Methyltestosterone, Metandren, Testred, Android, Androsten, 17α-Methyltestosterone, Dumogran, Malestrone, Masenone or Mastestona) is a hormone and steroid substance of the steroid class.
Chemistry
Stereochemistry []
Methyltestosterone is a single defined stereoisomer.
Druglikeness
Lipinski's rule of five
Methyltestosterone matches Lipinski's rule of five.Pharmacology
ATC Classification
- genito urinary system and sex hormones (G)
- sex hormones and modulators of the genital system (G03)
- androgens (G03B)
- 3-oxoandrosten (4) derivatives (G03BA)
- methyltestosterone (G03BA02)
- androgens and female sex hormones in combination (G03E)
- androgens and female sex hormones in combination with other drugs (G03EK)
- methyltestosterone (G03EK01)
MeSH Classification
Mechanism of action []
The effects of testosterone in humans and other vertebrates occur by way of two main mechanisms: by activation of the androgen receptor (directly or as DHT), and by conversion to estradiol and activation of certain estrogen receptors. Free testosterone (T) is transported into the cytoplasm of target tissue cells, where it can bind to the androgen receptor, or can be reduced to 5α-dihydrotestosterone (DHT) by the cytoplasmic enzyme 5α-reductase. DHT binds to the same androgen receptor even more strongly than T, so that its androgenic potency is about 2.5 times that of T. The T-receptor or DHT-receptor complex undergoes a structural change that allows it to move into the cell nucleus and bind directly to specific nucleotide sequences of the chromosomal DNA. The areas of binding are called hormone response elements (HREs), and influence transcriptional activity of certain genes, producing the androgen effects. [1]
Medical side effects []
25 side effects listed on drug labels in SIDER 4.1 (methyltestosterone).
- Alopecia
- Amenorrhoea
- Anxiety
- Coagulopathy
- Libido decreased
- Disturbance in sexual arousal
- Gynaecomastia
- Headache
- Haemorrhage
- Haemoglobin
- Hirsutism
- Jaundice cholestatic
- Nausea
- Azoospermia
- Peliosis hepatis
- Polycythaemia
- Angiopathy
- Virilism
- Paraesthesia
- Enlarged clitoris
- Menstruation irregular
- Anaphylactic shock
- Anaphylactoid reaction
- Blood cholesterol increased
- Embolism venous
Indications
- Breast cancer
- Cryptorchism
- Delayed puberty
- Hypogonadism male
- Neoplasm
- Orchitis
- Primary hypogonadism
- Puberty
- Secondary hypogonadism
- Testosterone deficiency
- Trauma
Legal status []
- Brazil: Methyltestosterone is a C5.[4]
- Canada: Methyltestosterone is a Schedule IV.
- United States: Methyltestosterone is a Schedule III under the "Controlled Substances Act".
- Australia: Methyltestosterone is a Schedule 4.
- Other: Methyltestosterone is a Rx-only.
See also []
External links []
- Methyltestosterone (Wikipedia)
- Methyltestosterone (PubChem)
- Methyltestosterone (Wikidata)
- Methyltestosterone (DrugBank)
- Methyltestosterone (ChEMBL)
- Methyltestosterone (ChEBI)
- Methyltestosterone (Common Chemistry)
- Methyltestosterone (HMDB)
- Methyltestosterone (KEGG)
- Methyltestosterone (EPA DSSTox)
- Methyltestosterone (Effect Index)
- Methyltestosterone (UNII)
- Methyltestosterone (SIDER)
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 6010, Methyltestosterone. Accessed November 22, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/6010
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Methyltestosterone. UNII: V9EFU16ZIF. Global Substance Registration System. Accessed November 22, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/V9EFU16ZIF
Behre HM, Wang C, Handelsman DJ, Nieschlag E. Testosterone. 2004. https://doi.org/10.1017/CBO9780511545221.015
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 2023-03-31. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 04:51:38 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 04:51:34 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 04:51:34 |
| gsrs | ok | 2026-11-20 04:51:35 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0015655) | 2026-11-20 04:51:34 |
| kegg | ok | 2026-11-20 04:51:36 |
| pubchem | ok | 2026-11-20 04:51:34 |
| missing (no r/tripreports posts mention it) | 2026-11-20 04:51:34 | |
| sider | ok | 2026-11-20 04:51:34 |
| structure | ok | 2026-11-20 04:51:34 |
| wikipedia | ok | 2026-11-20 04:51:34 |